| 中文名 | GSK 2830371 |
| 英文名 | GSK 2830371 |
| 别名 | (S)-5-(((5-氯-2-甲基吡啶-3-基)氨基)甲基)-N-(3-环戊基-1-(环丙基氨基)-1-氧代丙烷-2-基)噻吩-2-甲酰胺 (S)-5-((((5-氯-2-甲基吡啶-3-基)氨基)甲基)-N-(3-环戊基-1-(环丙基氨基)-1-氧丙烷-2-基)噻吩-2 -羧酰胺 |
| 英文别名 | GSK 2830371 (S)-5-((5-chloro-2-methylpyridin-3-ylamino)methyl)-N-(3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl)thiophene-2-carboxamide 5-[[(5-Chloro-2-methyl-3-pyridinyl)amino]methyl]-N-[(1S)-1-(cyclopentylmethyl)-2-(cycloprpylamino)-2-oxoethyl]-2-thiophenecarboxamide 5-[[(5-Chloro-2-methyl-3-pyridinyl)amino]methyl]-N-[(1S)-1-(cyclopentylmethyl)-2-(cyclopropylamino)-2-oxoethyl]-2-thiophenecarboxamide 2-Thiophenecarboxamide, 5-[[(5-chloro-2-methyl-3-pyridinyl)amino]methyl]-N-[(1S)-1-(cyclopentylmethyl)-2-(cyclopropylamino)-2-oxoethyl]- GSK 2830371 (S)-5-(((5-chloro-2-methylpyridin-3-yl)amino)methyl)-N-(3-cyclopentyl-1-(cyclopropylamino) -1-oxopropan-2-yl)thiophene-2-carboxamide |
| CAS | 1404456-53-6 |
| 化学式 | C23H29ClN4O2S |
| 分子量 | 461.02 |
| 密度 | 1.30±0.1 g/cm3(Predicted) |
| 沸点 | 704.1±60.0 °C(Predicted) |
| 溶解度 | DMSO: 可溶20mg/mL,澄清 |
| 酸度系数 | 13.29±0.46(Predicted) |
| 存储条件 | 2-8°C |
| 外观 | 粉末 |
| 颜色 | white to beige |
| 体外研究 | In the PPM1D-amplified MCF7 breast carcinoma cells, GSK2830371 increases the phosphorylation of multiple Wip1 substrates, including p53 (S15), Chk2 (T68), H2AX (S139) and ATM (S1981). GSK2830371 shows selective antiproliferative activity in a subset of lymphoid cell lines, all of which carry a wild-type TP53 allele. Furthermore, co-treatment of doxorubicin and GSK2830371 results in a synergistic antiproliferative effect in DOHH2 and MX-1 tumor cells. 在PPM1D扩增的MCF7乳腺癌细胞中,GSK2830371增加多重Wip1底物,包括p53 (S15),Chk2 (T68),H2AX (S139) 和 ATM (S1981)的磷酸化。GSK2830371在一部分携带野生型TP53等位基因的淋巴样细胞系中表现出选择性抗增殖活性。此外,doxorubicin 和 GSK2830371共处理在DOHH2和MX-1肿瘤细胞中表现出协同的抗增殖作用。 |
| 体内研究 | In vivo, GSK2830371 increases phosphorylation of Chk2 (T68) and p53 (S15) and decreases Wip1 protein concentrations in DOHH2 tumors. GSK2830371 (150 mg/kg p.o.) also inhibits the growth of DOHH2 tumor xenografts via inhibition of Wip1. 在体内,GSK2830371增加Chk2 (T68) 和 p53 (S15)的磷酸化,并减少DOHH2肿瘤中Wip1蛋白质浓度。GSK2830371 (150 mg/kg p.o.)通过抑制Wip1也会抑制DOHH2肿瘤异种移植物的生长。 |
| WGK Germany | 3 |
| 上游原料 | 2,5-二氯-3-硝基吡啶 3-氨基-5-氯甲基吡啶 5-氯-2-甲基-3-硝基吡啶 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.169 ml | 10.846 ml | 21.691 ml |
| 5 mM | 0.434 ml | 2.169 ml | 4.338 ml |
| 10 mM | 0.217 ml | 1.085 ml | 2.169 ml |
| 5 mM | 0.043 ml | 0.217 ml | 0.434 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!